Protocol
12-148
Full Title
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients with Relapsed or Refractory AML
Purpose
Acute myeloid leukemia (AML) can be difficult to treat. Some patients who experience a relapse of their disease or whose AML does not respond to initial therapy are unable to tolerate the side effects of additional chemotherapy. Doctors are therefore seeking new treatments for this disease.
Tigecycline is an antibiotic that has been shown in laboratory studies to kill leukemia cells. In this study, researchers want to identify the highest dose of tigecycline that can be given safely in patients with AML that has persisted or returned despite prior therapy.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have AML that has persisted or returned despite prior therapy.
- Patients must have recovered from the side effects of prior therapy.
- Patients who are allergic to tetracycline or minocycline may not participate.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Martin Tallman at 212-639-3842.
Disease(s)
Leukemia
Leukemia: Acute Myelocytic Leukemia
Leukemia: Acute Myelogenous Leukemia
Locations
Related Diseases
